ASX Growth Stocks With High Insider Ownership

The Australian market has recently experienced a mixed performance, with materials dragging down the indices while energy stocks showed resilience amid shifting global economic sentiments. In this context, growth companies with high insider ownership can be particularly appealing as they often indicate strong internal confidence and alignment of interests, making them worth considering in today's fluctuating market environment.

Top 10 Growth Companies With High Insider Ownership In Australia

Name	Insider Ownership	Earnings Growth
Wisr (ASX:WZR)	12.6%	89.9%
Titomic (ASX:TTT)	11.3%	74.9%
Pointerra (ASX:3DP)	19%	110.3%
Newfield Resources (ASX:NWF)	31.5%	72.1%
IRIS Metals (ASX:IR1)	21.1%	144.4%
Gratifii (ASX:GTI)	13.9%	137.7%
Findi (ASX:FND)	33.6%	91.2%
Echo IQ (ASX:EIQ)	19.1%	49.9%
Adveritas (ASX:AV1)	18.8%	96.8%
Acrux (ASX:ACR)	15.9%	121.1%

Click here to see the full list of 98 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

We're going to check out a few of the best picks from our screener tool.

Mesoblast (ASX:MSB)

Simply Wall St Growth Rating: ★★★★★★

Overview: Mesoblast Limited, with a market cap of A$3.46 billion, develops regenerative medicine products across Australia, the United States, Singapore, and Switzerland.

Operations: The company's revenue segment is primarily derived from the development of its cell technology platform for commercialization, generating $17.20 million.

Insider Ownership: 34%

Earnings Growth Forecast: 56.1% p.a.

Mesoblast, a growth company with high insider ownership, is forecasted to achieve profitability within three years and outpace the market in revenue growth at 44.5% annually. Recent substantial insider buying signals confidence in its trajectory. The recent activation of a permanent J-Code for Ryoncil® by U.S. Medicare & Medicaid Services enhances billing and reimbursement processes, potentially expanding patient access and sales opportunities. Additionally, Mesoblast's convertible note issuance suggests strategic financial planning to support future growth initiatives.

• Take a closer look at Mesoblast's potential here in our earnings growth report.
• Our valuation report here indicates Mesoblast may be undervalued.

PWR Holdings (ASX:PWH)

Simply Wall St Growth Rating: ★★★★★☆

Overview: PWR Holdings Limited specializes in the design, production, and sale of cooling products and solutions across various international markets, with a market capitalization of A$854.88 million.

Operations: The company generates revenue from its PWR C&R segment amounting to A$42.33 million and PWR Performance Products segment totaling A$101.83 million.

Insider Ownership: 13.4%

Earnings Growth Forecast: 26.8% p.a.

PWR Holdings demonstrates strong growth potential with forecasted earnings growth of 26.8% annually, outpacing the Australian market. Despite a recent decline in profit margins from 17.8% to 7.5%, insider transactions show more buying than selling, indicating confidence in future prospects. Revenue is expected to grow at 13.8% per year, faster than the market average of 7.7%. The company is trading slightly below its estimated fair value and maintains high-quality earnings despite recent leadership changes and strategic board appointments.

• Unlock comprehensive insights into our analysis of PWR Holdings stock in this growth report.
• The valuation report we've compiled suggests that PWR Holdings' current price could be inflated.

Telix Pharmaceuticals (ASX:TLX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals, with a market cap of A$5.69 billion.

Operations: The company's revenue is primarily derived from Precision Medicine, generating $575.13 million, followed by Manufacturing Solutions at $115.57 million and Therapeutics contributing $7.29 million.

Insider Ownership: 14.9%

Earnings Growth Forecast: 47.5% p.a.

Telix Pharmaceuticals is positioned for substantial growth, with earnings projected to expand at 47.5% annually, significantly outpacing the Australian market. Recent revenue guidance was increased to A$800 million-A$820 million for 2025, reflecting robust performance and strategic advancements like the U.S. CMS designation for Gozellix. Despite lower profit margins this year and debt coverage concerns, Telix trades well below its estimated fair value and maintains a high forecasted return on equity of 20.5%.

• Delve into the full analysis future growth report here for a deeper understanding of Telix Pharmaceuticals.
• Upon reviewing our latest valuation report, Telix Pharmaceuticals' share price might be too pessimistic.

Where To Now?

• Click through to start exploring the rest of the 95 Fast Growing ASX Companies With High Insider Ownership now.
• Interested In Other Possibilities? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com